Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dediffentiating an induced pluripotent stem cell. Also, the present invention relates to a method for producing induced pluripotent stem cells using the medium composition. When using the medium composition, according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced safely, easily, and efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into a variety of cells.

Abstract: A polypeptide composition induces a pluripotent stem cell culturing property, particularly, an excellent cell growth ability. The polypeptide composition contains a predetermined polypeptide including an amino acid sequence of human vitronectin or an amino acid sequence of a predetermined first region derived from human vitronectin. The polypeptide composition includes a multimeric polypeptide, which is composed of two or more monomers held together by intermolecular cross-linking via cysteine residues included in the first region, in an amount equal to or less than 20% by mass of a total mass of polypeptides contained in the composition. A culture method for pluripotent stem cells includes culturing pluripotent stem cells in the presence of the polypeptide composition. Also provided is a culture vessel including a support which has a cell culture surface and the polypeptide contained in the polypeptide composition disposed on the cell culture surface of the support.

Abstract: Provided is a novel bacteriophage ?CJ23 (KCCM11365P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ?CJ23 (KCCM11365P) as an active ingredient. Further, provided is a method of preventing and/or treating infectious diseases by avian pathogenic Escherichia coli (APEC) in birds using the bacteriophage ?CJ23 (KCCM11365P) or the antibacterial composition containing the bacteriophage ?CJ23 (KCCM11365P) as an active ingredient.

Abstract: The present invention provides methods of propagating rhinovirus C (RV-C) in a host cell; a host cell comprising an effective amount of a heterologous CDHR3 receptor such that the host cell can support propagation of rhinovirus C; and kits comprising at least one host cell previously unable to support rhinovirus C growth, wherein the host cell comprises a heterologous CDHR3 receptor and a sample of rhinovirus C. Methods of use are also provided.

Abstract: The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

Abstract: The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (?)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

Abstract: The present invention provides Photobacterium sp. JH-ISH-224 ?2-6-sialyltransferase Psp26ST variants and expression cassettes, vectors, and host cells for expressing the Psp26ST variants. Methods of synthesizing sialylated products are also described.

Abstract: The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at one or more residues of the thumb region, said residues selected from: amino acids 651 to 679 (patch 10A); wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue E664. In one embodiment said polymerase comprises the mutations Y409G and E664K. In one embodiment said polymerase comprises amino acid sequence corresponding to SEQ ID NO:12.

Abstract: The present invention relates to an isolated polynucleotide comprising an open reading frame encoding a polypeptide having alpha-amylase activity, the polypeptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence which has at least 70% identity with amino acids 22 to 450 of SEQ ID NO: 4; b) a polypeptide comprising an amino acid sequence which has at least 70% identity with the polypeptide encoded by the amylase encoding part of the polynucleotide inserted into a plasmid present in the E. coli host deposited under the Budapest Treaty with DSMZ under accession number DSM 15334; c) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence which has at least 70% identity with the sequence shown from position 68 to 1417 in SEQ ID NO: 3; and d) a fragment of (a), (b) or (c) that has alpha-amylase activity.

Abstract: The present invention relates to methods of increasing the activity of a polypeptide having cellulolytic enhancing activity, comprising: adding a soluble activating divalent metal cation to a composition comprising the polypeptide having cellulolytic enhancing activity, wherein the presence of the soluble activating divalent metal cation and the polypeptide having cellulolytic enhancing activity increases degradation or conversion of a cellulose-containing material by a cellulolytic enzyme composition compared to the polypeptide having cellulolytic enhancing activity without the soluble activating divalent metal cation. The present invention also relates to compositions, methods for degrading or converting a cellulose-containing material, and methods for producing a fermentation product.

Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.

Abstract: The present invention relates to: a D-psicose 3-epimerase mutant from Agrobacterium tumefaciens with improved thermal stability; a recombinant vector comprising a gene encoding the mutant; and a microorganism comprising the mutant. In addition, the present invention relates to a method for producing D-psicose by using the epimerase mutant or the microorganism.

Abstract: The invention provides methods and compositions for a mutein aminoacyl-tRNA synthetase that preferentially charges a tRNA with a non-natural amino acid. Also provided are methods for incorporating the non-natural amino acid, para-methylazido-L-phenylalanine into a protein and further conjugating a biologically active adduct to the para-methylazido-L-phenylalanine.

Abstract: The invention provides small enzyme-containing granules having an inorganic salt core and an enzyme-containing layer coated over the core, and methods for producing such granules. The majority of the enzyme granules are less than 300 ?m in diameter. The granules are suitable for incorporation into compositions such as cleaning, textile processing, and animal feed compositions.

Abstract: Devices are provided for inhibiting the electrical activity of an excitable cell through the application of a pulse of light which includes a substrate and a photoreactive film both of non-conducting material and laid directly on one another, in which the photoreactive film includes a layer of semiconductor polymer material and has an interface surface which can be placed in contact with an excitable cell and an electrolyte solution. After absorbing light, when placed in contact with the excitable cell and the electrolyte solution, the photoreactive film produces a potential difference across this interface surface which is capable of giving rise to hyperpolarization of the membrane of the excitable cell. Methods of inhibiting the electrical activity of excitable cells using such devices are also provided.

Abstract: The present invention relates to methods and systems for the isolation of DNA on a microfluidic device and the subsequent analysis of the DNA on the microfluidic device. More specifically, embodiments of the present invention relate to methods and systems for the isolation of DNA from patient samples on a microfluidic device and use of the DNA for performing amplification reactions, such as PCR, and detection, such as thermal melt analysis, on the microfluidic.

Abstract: The present invention provides a cost-efficient method for producing particles having a SiO2 containing surface wherein said method comprises a) providing an aqueous reaction composition comprising i) core particles, ii) an added base, iii) a silicate salt, and iv) a pH modulator wherein the pH value of the reaction composition is above the gelation pH value; b) agitating said reaction composition, wherein the pH modulator decreases the pH value of the reaction composition over time and wherein due to said decrease of the pH value of the reaction composition SiO2 is deposited onto the core particles, whereby particles are formed which have a diameter of 30 ?m or less; and c) obtaining the particles. Furthermore, silica particles having high nucleic acid binding properties are provided.

Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.

Abstract: This invention relates to linking, amplifying and sequencing of two ends of long linear DNAs. In particular, this invention provides methods for pairing and sequencing VH and VL genes that encode two parts of one immunoglobulin. The method of the present invention can be applied to rapid antibody discovery and engineering.

Abstract: Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display) are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide.

Abstract: The invention provides novel methods and materials for genetic and genomic analysis using single or multiplex isolation of protein-associated nucleic acids, including transposase-assisted chromatin immunoprecipitation (TAM-ChIP) and antibody-oligonucleotide proximity ligation. These methods comprise tagging and isolating chromatin or other protein-associated nucleic acids and using antibody-oligonucleotide complexes that recognize the proteins associated with such nucleic acids.

Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalized by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.

Abstract: The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins. Although this receptor has particular affinity for manganese, it is contemplated that other divalent ions, including magnesium, calcium, and the like may also be bound to such receptors leading to transport of the nanoparticles into the intracellular cytoplasm. Nanoparticles have been developed, therefore, as vehicles for parenteral delivery of genes, proteins and drugs.

Abstract: The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5?-(Tx)GxGxcsasasgscsastscscsTxGxT-3? and 5?-(Gx)TxTxascstsgscscststscsTxTxA-3?, wherein capital letters designate a beta-D-oxy-LNA nucleotide analog, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analog or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogs, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighboring nucleotides/LNA nucleotide analogs, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g.

Abstract: The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

Abstract: Double-stranded and single-stranded RNA molecules, and their use in methods for inducing interferon are provided. The interferon induction provides anti-viral and other medically useful effects, such as anti-cancer effects. Also provided are methods for reducing or inhibiting interferon induction exhibited by such molecules, particularly siRNA and shRNA molecules produced in vitro.

Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.

Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.

Abstract: The invention relates to an aptamer, the structure thereof comprising at least one nucleotide sequence 5?-GGCA(A/G)GGA-3?, that can specifically bind to the poly(A) hairpin of the 5?UTR region of the genome of the human immunodeficiency virus type 1 (HIV-1), providing the method for producing aptamers with said sequence by means of a combination of experimental techniques of in vitro selection of nucleic acids with computational techniques of sequence optimization. The invention also relates to a DNA gene structure for synthesizing said aptamers, preferably RNA. The invention further relates to the different uses of the above-mentioned aptamer, including the use thereof as a biosensor molecule for detecting and/or quantifying HIV-1, as an inhibitor of the production of viral particles of HIV-1, and to the application thereof in medicine, the invention also relating to a method for treating a disease caused by HIV-1, and to a pharmaceutical composition comprising said aptamer.

Abstract: Disclosed are short DNA aptamers that selectively recognize CD200R1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, CD200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorders such as systemic lupus erythematosus, Parkinson's Disease, or multiple sclerosis.

Abstract: Recombinant DNA molecules and constructs useful for modulating gene expression in plants, including molecules derived from Medicago truncatula sequences, are provided. Transgenic plants, plant cells, plant parts, and seeds comprising recombinant DNA molecules operably linked to heterologous transcribable DNA molecules are further provided, as are methods of their use.

Abstract: Recombinant DNA molecules and constructs useful for modulating gene expression in plants, including molecules derived from Medicago truncatula sequences, are provided. Transgenic plants, plant cells, plant parts, and seeds comprising recombinant DNA molecules operably linked to heterologous transcribable DNA molecules are further provided, as are methods of their use.

Abstract: Methods and materials for modulating aluminum tolerance in plants are disclosed. For example, nucleic acids encoding aluminum tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased tolerance to aluminum and methods of increasing plant yield in soil containing elevated levels of aluminum.

Abstract: Methods and compositions for increasing a plant's resistance to an insect pest such as the corn rootworm are provided. Methods are provided for overexpression of Crw2, or variants thereof, in a host plant or plant cell to increase resistance to an insect pest in a plant such as maize. Methods are also provided for identifying variants of Crw2 that when incorporated into a plant via transgenic or traditional breeding means increase resistance to an insect pest in a plant such as maize. Also provided are methods for increasing resistance by overexpressing Crw1 and Crw2.

Abstract: The present disclosure relates to a fertility gene and the use thereof, and relates to the biotechnology field, particularly to a method of plant hybrid breeding including creation of a sterile line and preparation of hybrid seeds, more particularly to a fertility gene FL2, a mutant thereof and use thereof in hybrid breeding.

Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.

Abstract: A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells.

Abstract: The invention provides an AAV particle containing an adeno-associated viral (AAV) capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 of the sequence listing; a nucleic acid that encodes this capsid protein; DNA containing this nucleic acid; a cell containing this DNA; and a method for producing this cell.

Abstract: Mixotrophic fermentation method performed to make one or more bioproducts such as alcohols, organic acids of less than 7 carbons, acetone, 2,3-butanediol and mixtures thereof with a microorganism. The mixotrophic fermentation method includes providing an isolated organism and providing a first feedstock and a second feedstock for use in a fermentation medium. The first feedstock includes a carbon source that is metabolized by the native form of the organism at a rate of less than 0.01 g/hr/g cell mass, and the second feedstock includes CO, CO2, carbonate, bicarbonate, H2, glycerol, methanol, formate, urea or mixtures thereof. The mixotrophic fermentation method also includes culturing the organism in the fermentation medium, whereby both feedstocks are metabolized and a fermentation broth is formed, the broth having at least one bioproduct. Optionally, the bioproduct may be separated from the broth.

Abstract: This document describes biochemical pathways for producing 2,4-pentadienoyl-CoA by forming one or two terminal functional groups, comprised of carboxyl or hydroxyl group, in a C5 backbone substrate such as glutaryl-CoA, glutaryl-[acp] or glutarate methyl ester. 2,4-pentadienoyl-CoA can be enzymatically converted to 1,3-butadiene.

Abstract: The technology relates in part to biological methods for producing a fatty dicarboxylic acid and engineered microorganisms capable of such production.

Abstract: The present invention relates to a genetically engineered algae strain in which the expression of the CGI-58 gene or homologous gene thereof is silenced. The present invention further relates to a method of triacylglycerol accumulation using said genetically engineered diatom and/or diatom strain.

Abstract: The present invention relates to a modified polynucleotide encoding aspartate kinase (EC:2.7.2.4; hereinafter, referred to as LysC), transketolase (EC:2.2.1.1; hereinafter, referred to as Tkt) or pyruvate carboxylase (EC:6.4.1.1; hereinafter, referred to as Pyc), in which the initiation codon is substituted with ATG, a vector including the same, a microorganism transformed with the vector, and a method for producing L-lysine using the same.

Abstract: The invention is directed to a process for the preparation of 2,5-furandicarboxylic acid (FDCA) by fermentation comprising fermenting a suitable starting compound to produce an aqueous solution of a salt of FDCA having a pH of at least 7, optionally removing solids from said solution, e.g. by filtration, subsequently freeze crystallizing the said salt of FDCA from said solution at said pH, isolating the said FDCA salt in the form of solid crystals, preparing an aqueous solution of said salt and crystallizing FDCA as the free acid from said solution at an acidic pH.

Abstract: The invention relates to a process for preparing a compound of the formula (I), in which R is H or C1-C6 alkyl, by reaction of at least one compound of the formula (II) in which R has the same definition as in the formula (I) and in which R1 is H, C1-C12 alkyl or C3-C12 cycloalkyl, with a compound of the formula (III) in which R2 is H or C(O)R3, in which R3 is H or C1-C12 alkyl, in the presence of at least one enzyme suitable for transesterification.

Abstract: The present invention relates to a process for producing a monosaccharide using a microorganism. The microorganism possesses a glycosyltransferase and a glycosidase which work together to synthesize a desired monosaccharide in free form by using an endogenous provided nucleotide activated monosaccharide, glycosylate a suitable acceptor substrate and release the desired monosaccharide by a hydrolysis reaction. The required acceptor substrate for the reaction is recycled and only needed in catalytic amounts. The monosaccharide is produced in free from and is retrieved from the supernatant of the cultivated microorganism.

Abstract: The present application provides a culture medium for producing ?-glucan. The culture medium comprises: a carbon source, a nitrogen source and an ascorbic acid. The present application further provides a method for producing ?-glucan, the method comprising culturing Aureobasidium pullulans in the culture medium for fermentation. The Aureobasidium pullulans is advantageous in producing no melanin; as a result, the yield of ?-glucan can be increased and the waste can be reduced with the improved culture medium composition and culturing method.

Abstract: Disclosed are a number of homologs and variants of Hypocrea jecorina Ce17A (formerly Trichoderma reesei cellobiohydrolase I or CBH1), nucleic acids encoding the same and methods for producing the same. The homologs and variant cellulases have the amino acid sequence of a glycosyl hydrolase of family 7A wherein one or more amino acid residues are substituted and/or deleted.

Abstract: The invention relates to methods of saccharifying a cellulosic material comprising subjecting the cellulosic material to a catalase and a cellulolytic enzyme composition comprising a GH61 polypeptide in the presence of dissolved oxygen at a concentration of greater than 10% of the saturation level. The invention also related to methods of producing desired fermentation products, such as ethanol, using a method including a saccharification step of the invention.

Abstract: Disclosed are devices and methods to synthesize polynucleotides and libraries of polynucleotides such as libraries of oligonucleotides. In exemplary embodiments, the device includes a support having a plurality of features. Each feature contains a plurality of oligonucleotides. Within each feature, each of the plurality of oligonucleotides includes an identical predetermined subunit sequence of X nucleosides and a degenerate sequence of Y nucleosides. A predetermined combination of a subset of the features can be used to produce a polynucleotide having a predetermined sequence of Z nucleosides.